Contract manufacturing market for live biotherapeutics and microbiome products
Health

Contract manufacturing market for live biotherapeutics and microbiome products

damon987
damon987
3 min read


With over 85 microbiome-based, live biotherapeutic products under preclinical and clinical development, the demand for R&D and manufacturing services for such products is anticipated to increase beyond the capabilities of innovator companies alone

 

London

Roots Analysis has announced the addition of “Live Biotherapeutic Products and Microbiome Contract Manufacturing Market, 2020-2030: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms, 2020-2030 report to its list of offerings.

Manufacturing live biotherapeutic products is both technically challenging and financially demanding; as a result, innovator firms are becoming increasingly reliant on contract service providers to access specialized facilities and optimize overall costs.

To order this 300+ page report, which features 140+ figures and 125+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/microbiome-contract-manufacturing/306.html

The research covers detailed profiles brief profiles of several companies (including those listed below); each profile features an overview of the company, its financial information (if available), microbiome-related service portfolio, facilities dedicated to microbiome manufacturing, and an informed future outlook.

Biose®BJP LaboratoriesCapsugel (acquired by Lonza)Cerbios-PharmaCobra Biologics (acquired Cognate Bioservices)Inpac ProbioticsParagon Bioservices (a unit of Catalent Biologics)UAS Labs

For additional details, please visit

https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html or email sales@rootsanalysis.com

You may also be interested in the following titles:

HPAPI and Cytotoxic Drugs Manufacturing Market (3rd Edition), 2020-2030Antibody Contract Manufacturing Market, 2020 – 2030The Human Microbiome Market: Focus on Therapeutics (including gut-brain axis targeting drugs), Diagnostics and Fecal Microbiota Therapies (3rd Edition), 2019-2030

Contact:

Gaurav Chaudhary

+1 (415) 800 3415

 +44 (122) 391 1091

Gaurav.Chaudhary@rootsanalysis.com

Discussion (0 comments)

0 comments

No comments yet. Be the first!